Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigious | ||
| Readability |
H.S. senior Avg
|
|
New words:
adherence, ADR, aforementioned, Aimmune, AKS, Allele, allergen, alleviate, antitrust, approach, arisen, arm, array, asymptomatic, atoltivimab, awaiting, belonging, Biden, bioresearch, birch, Black, bond, bore, career, carefully, casirivimab, certified, child, chosen, closure, coaching, cogent, Colorado, Commonwealth, complimenting, conclusive, confirmatory, constantly, contamination, costimulatory, counterclaim, countermeasure, credible, CRS, crucial, curtailment, Deficiency, denominator, diagnose, DIRA, disapprove, distancing, driven, dyslipidemia, economy, edited, EEA, EHS, elder, elongation, emotional, empowered, engraftment, enjoined, Enlarged, enteropathy, ergonomic, escape, ESMO, essential, ethnic, ethnicity, EUA, Evkeeza, EvkeezaTM, exact, extortion, facilitate, fatal, Female, flexibility, flexible, forbidding, formal, Fortune, foster, fostering, fungal, futility, gather, geographic, gift, GITR, globe, guide, heightened, heightening, hemophilia, Hereditary, homegrown, Hong, hour, household, housemate, Iceland, imdevimab, immunodeficient, impede, indemnity, Inmazeb, InmazebTM, insert, intake, intervention, IRB, ITC, itepekimab, job, join, justifying, Jyseleca, kg, Kong, Lab, Labour, leader, leadership, leaseback, leave, Leqvio, Liechtenstein, lifted, Macau, maftivimab, magnitude, main, mainland, Mayo, meditation, mental, mentally, MFN, microbial, mission, movement, mutant, myasthenia, NEJM, Neoadjuvant, nephropathy, NIAID, NIH, NMPA, Northern, Norway, notified, nurse, odronextamab, omalizumab, online, onsite, ordinary, organizational, outlining, outreach, outweigh, overage, Overnight, oversee, overturned, Oxford, oxygen, pandemic, passive, pause, pausing, PBM, PFS, pharmacovigilance, philosophy, PIP, pollen, postponement, predetermined, prioritization, proceed, proud, prurigo, PSMF, PSU, pulse, purity, QPPV, quarantine, question, race, racial, Racketeer, ransomware, recession, recipient, recoup, redeem, redeemed, remote, repaid, repay, repeatedly, representation, restraining, resume, retention, Rinat, rollout, room, seronegative, shelter, Sherman, SOFR, Solicitor, sooner, spike, spread, spring, steering, strain, strength, surveillance, survey, symptomatic, talent, Tariff, transthyretin, treble, trend, TTR, tuition, UCLA, UHC, unacceptable, underage, underpinning, underrepresented, uninfected, UnitedHealthcare, University, upside, urgency, urgent, vaccination, vaccine, VelociHum, ventilation, Vetter, video, virology, Virtual, volunteerism, warning, weighing, wellbeing, whistleblower, willfully, Women, workforce, workplace, worn, Wuhan, Zai, Zaire
Removed:
AbbVie, accommodate, acute, afflicted, analyzing, appoint, basal, Biogen, category, ceased, cGCP, clarification, closely, comprise, concomitant, conspiracy, constitute, consultant, consummated, consummation, daily, deductibility, define, deny, deployed, destination, Directive, diverse, elevated, evidenced, execute, exhausted, expensing, FOB, foundational, freight, functional, genotyping, guaranteed, highest, intent, kind, modulate, municipal, Nordisk, novelty, Novo, pcJIA, predecessor, preserving, proportionately, proposal, recommending, refractory, remained, renovated, repeal, repealing, stipulate, sum, sustaining, taxation, tender, Threshold, toxicology, treaty, Trump, underwriter, underwritten, Unlimited, vi, waive
Filing tables
Filing exhibits
- 10-K Annual report
- 10.3.1 Stock Option Agreement (NQ) - Executive Officers
- 10.3.2 Stock Option Agreement (NQ) - P. Roy Vagelos
- 10.3.3 Restricted Stock Agreement - Executive Officers
- 10.3.4 Restricted Stock Agreement - P. Roy Vagelos
- 10.3.5 Stock Option Agreement (NQ) - Non-employee Directors
- 10.3.6 Restricted Stock Agreement - Non-employee Directors
- 10.3.7 Performance Restricted Stock Unit Agreement
- 10.34 Project Agreement by and Between the Registrant and Ati
- 10.34.1 Modification 01 to Project Agreement by and Between the Registrant and Ati
- 10.34.2 Modification 02 to Project Agreement by and Between the Registrant and Ati
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of CEO Pursuant to Rule 13A-14(A)
- 31.2 Certification of CFO Pursuant to Rule 13A-14(A)
- 32 Certification of CEO and CFO Pursuant to 18 U.s.c. Section 1350
- Download Excel data file
- View Excel data file
Related press release
Associated REGN transcripts
REGN similar filings
Filing view
External links
Exhibit 32
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Regeneron Pharmaceuticals, Inc. (the "Company") on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Leonard S. Schleifer, M.D., Ph.D., as Principal Executive Officer of the Company, and Robert E. Landry, as Principal Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| /s/ Leonard S. Schleifer | ||
| Leonard S. Schleifer, M.D., Ph.D. | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| February 8, 2021 | ||
| /s/ Robert E. Landry | ||
| Robert E. Landry | ||
| Executive Vice President, Finance and Chief Financial Officer | ||
| (Principal Financial Officer) | ||
| February 8, 2021 | ||